News
-
-
PRESS RELEASE
Screening completed: Berlin Cures achieves key milestone in BC 007 Phase II Trial for treatment of Long COVID
Berlin Cures achieves key milestone in BC 007 Phase II trial for Long COVID treatment by successfully completing patient screening, marking a significant step in developing an effective therapy -
-
-
-
PRESS RELEASE
Berlin Cures' BC 007 Targets Long COVID: Solid Phase II Trial Progress with Over 50% Patient Recruitment
Berlin Cures reaches over 50% patient recruitment in Phase II trial for Long COVID treatment with BC 007, aiming to neutralize harmful autoantibodies. CEO emphasizes global impact and urgent need for innovative solutions -
-
-
Wood in Architecture Awards Celebrate Innovative & Resilient Design
-
PPX Mining Completes Debt Settlement Transaction
-
Arras Minerals Closes C$5.2 Million Non-Brokered Financing
-
Aston Bay Holdings Closes $2,137,860 Second Tranche of Non-Brokered Private Placement for $3,517,860 Total to Date
-
Apex Critical Metals Corp. Signs Earn-In Agreement with Discovery Lithium & DG Resource Management
-
Patrimonium Swiss Real Estate Fund: stable results in a difficult environment
-
Molten Ventures Plc: HOL-Holding(s) in Company
-
Eighteenth Annual General Meeting of Delticom AG
-
Annual General Meeting of CANCOM SE elects Supervisory Board and approves dividend of € 1.00
-
PNE AG successfully sells its US division to Lotus Infrastructure Partners
-
Shareholders’ Meeting and Board of Directors’ meeting on June 6, 2024
-
Disclosure of voting rights - 06.06.2024
-
Eurazeo announces the signing by Grape Hospitality of an exclusivity agreement for the sale of 23 hotels
-
Safran: Update on proposed acquisition of Collins Aerospace’s actuation and flight control business
-
Aéroports de Paris SA - Voting rights as of 31 May 2024